TetraLogic Pharmaceuticals Corporation

TLOG

US88165U1097

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 14:23:16 2024-05-28 EDT			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-99.00%

2020	Medivir AB Renegotiates its agreement with TetraLogic Pharmaceuticals Corporation	CI
2017	TetraLogic Pharmaceuticals Corporation Appoints Alexandre Zyngier to Board of Directors and Management	CI

TetraLogic Pharmaceuticals Corporation Announces Board Changes

January 31, 2014 at 04:18 pm

On January 29, 2014, John M. Gill and Brenda Gavin, D.V.M., each a director of TetraLogic Pharmaceuticals Corporation resigned from the board of directors of the company, effective immediately.

Latest news about TetraLogic Pharmaceuticals Corporation

Medivir AB Renegotiates its agreement with TetraLogic Pharmaceuticals Corporation	20-12-11	CI
TetraLogic Pharmaceuticals Corporation Appoints Alexandre Zyngier to Board of Directors and Management	17-01-18	CI
Tetralogic Pharmaceuticals Corporation Announces Management Resignations	16-12-29	CI
Medivir AB (OM:MVIR B) completed the acquisition of substantially all the assets of TetraLogic Pharmaceuticals Corporation.	16-12-28	CI
TetraLogic Pharmaceuticals Corporation(OTCPK:TLOG) dropped from S&P TMI Index	16-11-07	CI
TetraLogic Pharmaceuticals Corporation(OTCPK:TLOG) dropped from NASDAQ Composite Index	16-11-03	CI
Medivir AB (OM:MVIR B) entered into a definitive asset purchase agreement to acquire substantially all the assets of TetraLogic Pharmaceuticals Corporation for approximately $170 million.	16-11-01	CI
TetraLogic Pharmaceuticals Corporation Announces Resignation of Douglas Reed as M. D, Effective July 21, 2016	16-07-22	CI
TetraLogic Pharmaceuticals Corporation Announces Executive Changes	16-04-07	CI
TetraLogic Pharmaceuticals Corporation(NasdaqGM:TLOG) dropped from CRSP US Total Market Index	16-03-21	CI
TetraLogic Pharmaceuticals Corporation Auditor Raises 'Going Concern' Doubt	16-03-15	CI
TetraLogic Pharmaceuticals Corporation Announces Resignation of Douglas E. Onsi as Member of Board of Directors, Effective February 5, 2016	16-02-03	CI
TetraLogic Pharmaceuticals Corporation Announces Management Terminations; Authorizes the Implementation of a 19 Person Reduction in Staff	16-01-22	CI
TetraLogic Pharmaceuticals Corporation Announces Results of the Interim Analyses of Two Clinical Studies	16-01-06	CI
TetraLogic Pharmaceuticals Corporation Announces Resignation of Michael Steinmetz from the Board of Directors, Effective December 15, 2015	15-12-09	CI
TetraLogic Pharmaceuticals Corporation Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015; Provides Update on SHAPE Alopecia Areata Program	15-11-04	CI
TetraLogic Pharmaceuticals Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015	15-08-05	CI
Certain shares of TetraLogic Pharmaceuticals Corporation's Common Stock are subject to a Lock-Up Agreement Ending on 30-JUL-2015.	15-07-29	CI
TetraLogic Pharmaceuticals Corporation Provides Update on Hepatitis B Clinical Program	15-07-20	CI
TetraLogic Pharmaceuticals Mulls Acquisitions	15-04-30	CI
TetraLogic Announces Publication of Two Papers Describing Birinapant's Preclinical Activity in Chronic Hepatitis B	15-04-21	CI
TetraLogic Pharmaceuticals Corporation and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA(R) (Pembrolizumab) in Solid Tumors	15-04-20	CI
TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA(R) (pembrolizumab) in Solid Tumors	15-04-20	CI
TetraLogic Pharmaceuticals Corporation Announces Resignation of James N. Woody, M.D., Ph.D. as Director	15-03-13	CI
Tetralogic Pharmaceuticals Corporation Reports Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Clinical Update	15-02-26	CI

Chart TetraLogic Pharmaceuticals Corporation

Duration

Period

Chart TetraLogic Pharmaceuticals Corporation

More charts

TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company's segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company's histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
TETRALOGIC PHARMACEUTICALS CORPORATION	-99.00%	24
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.09%	21.96B
GENMAB A/S	-9.84%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs